{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'concentration). This population will be used for all correlation analyses of plasma kallikrein', 'inhibition and plasma BCX7353 concentrations.', '13.4.2.', 'General Considerations for Data Analysis', 'Descriptive summaries, figures, and listings for efficacy, safety, concentration, and PD results', 'will use data from subjects enrolled in this study alone.', 'In general, descriptive summaries will include n, mean, SD, median, minimum, and maximum', 'for continuous variables and n and percent for categorical variables. Summaries will be presented', 'by study visit.', 'Selected summaries will be repeated using data from the current study and BCX7353-302.', 'All individual subject data will be listed as measured. All statistical summaries and analyses will', 'be performed using SASR software (SAS Institute, Cary, North Carolina, USA).', '13.4.3.', 'Subject Demographic and Disposition Data', 'Demographic and disposition data will be summarized for the current study alone and using the', 'combined data.', 'Demographic data and baseline characteristics including age, gender, race and ethnicity, height,', 'weight, BMI, and HAE history, including medication history, will be summarized by treatment', 'group.', 'Subject disposition will be presented for all subjects. The number of subjects who complete the', 'study and those who discontinue from the study will be provided. The reasons for early', 'discontinuation also will be presented. A tabulation of the number of subjects exposed to study', 'drug and duration of exposure will also be presented for each treatment group. Treatment', 'adherence, dose interruptions, and reason for dose interruptions will be provided as summaries or', 'listed as appropriate.', '13.4.4.', 'Analysis of Efficacy Variables', 'The primary efficacy endpoint will be determined from Part 1 of the current study alone, using', 'the ITT population.', 'A supplemental analysis will combine data from the current study and Study BCX7353-302.', 'Analysis of data using the PP population will be conducted to support the combined efficacy', 'analysis.', 'Efficacy data will generally be summarized by treatment group and for both active doses', 'combined. Angioedema events will generally be summarized over the entire dosing period.', 'Selected analyses will be repeated using the steady-state or effective dosing period.', 'The entire dosing period (Day 1 through Day 168, inclusive) is the date of first dose to the last', 'dose on Day 168 + 24 hours, or 24 hours after the last dose of the study drug, whichever is', 'earlier.', 'The effective dosing period (Day 8 through first dose in Part 2) is the date of first dose + 7 days', 'to the date and time of first dose in Part 2 or the date of study treatment discontinuation +', '24 hours, for subjects who discontinue treatment prior to Part 2.', '97']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '13.4.4.1. Primary Efficacy Analysis', 'The primary efficacy endpoint is the rate of expert-confirmed angioedema events during dosing', 'in the entire treatment period of Part 1 of the current study.', 'The sample size considered feasible for enrollment in Japan has limited statistical power.', 'Therefore, a supplemental statistical analysis will be conducted using the combined monthly', 'angioedema event rate (investigator-confirmed attacks in Study BCX7353-302 and', 'expert-confirmed events in Study BCX7353-301) in the entire treatment period in the ITT', 'population. The angioedema event rate and the treatment comparisons between each BCX7353', 'dose and placebo in the rate of investigator- or expert-confirmed angioedema events during the', 'entire dosing period will be analyzed using a negative binomial regression model. The number of', 'investigator- or expert-confirmed angioedema events will be included as the dependent variable,', 'the treatment will be included as a fixed effect, the stratification variable (baseline monthly', 'angioedema event rate) will be included as a covariate, and the logarithm of duration on', 'treatment will be included as an offset variable. The estimated rate of angioedema events for', 'each treatment group, the treatment differences expressed as the angioedema event rate ratio', '(BCX7353 over placebo rate ratio), and their associated 95% confidence intervals (CIs) will be', 'provided from the negative binomial regression model. Monthly will be defined as 4 weeks.', 'The potential impact of missing data on the primary efficacy outcome will be explored.', 'Sensitivity analyses will be conducted to support the primary analysis. This will include analyses', 'based on subjects who completed the study and on those in the PP population.', '13.4.4.2. Secondary and Exploratory Efficacy Analyses', 'Part 1 secondary efficacy endpoints include:', 'Change from baseline in AE-QoL at Week 24 (total score)', 'Number and proportion of days with angioedema symptoms through 24 weeks', 'Rate of investigator- or expert-confirmed angioedema events during dosing in the', 'effective treatment period (beginning on Day 8 through Week 24)', 'Part 1 exploratory efficacy endpoints include:', 'Number and proportion of subjects with no angioedema events over 24 weeks', 'Use of medications to treat angioedema events over 24 weeks', 'The proportion of responders to study drug, separately defined as at least a 50%,', '70%, or 90% relative reduction in the rate of expert-confirmed angioedema events', 'during treatment compared with the baseline expert-confirmed angioedema event rate', 'For the combined analysis with Study BCX7353-302, treatment comparisons in the AE-QoL', 'total score change from baseline will be analyzed using an MMRM with restricted maximum', 'likelihood estimation and an unstructured covariance matrix. The estimated treatment difference', 'for each BCX7353 dose-placebo at each visit will be displayed together with the 95% CI and the', 'associated p-value. Primary inferences will be drawn from treatment differences for the changes', 'from baseline derived from the MMRM model through Week 24. The change from baseline in', 'the AE-QoL domain scores (function, fatigue, nutrition, and fear/shame) will also be analyzed', 'using a MMRM model.', '98']\n\n###\n\n", "completion": "END"}